New study tracks duchenne muscular dystrophy from birth to age 3
NCT ID NCT07092540
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 105 boys from birth to age 3 who have Duchenne muscular dystrophy (DMD), identified through newborn screening. Researchers will measure motor and cognitive skills over time to understand how the disease develops in early childhood. The goal is to gather information that could help design future treatments and care strategies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Rochester
RECRUITINGRochester, New York, 14618, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug help boys with duchenne muscular dystrophy build muscle protein?
- New drugs aim to slow muscle decline in duchenne muscular dystrophy
- AI-Powered heart scans aim to predict deadly complications in muscular dystrophy
- Wearable sensors could bring duchenne monitoring home
- Could a popular Weight-Loss drug help—or Harm—Those with duchenne muscular dystrophy?
- New drug could help boys with duchenne walk and move longer